This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second View: Examining Amylyx' AMX0035 in ALS before the March 30th FDA ADCOM

Ticker(s): AMLX

Who's the expert?

Institution: University of Chicago

  • Marjorie and Robert E. Straus Professor of Neurology & Director, Amyotrophic Lateral Sclerosis/Motor Neuron Disease Clinic at the University of Chicago.
  • Currently manages about 150 patients with ALS
  • Lab uses viruses and transgenic mouse models in order to clarify the mechanisms by which mutant genes kill the target neurons.

Interview Questions
Q1.

Please describe your clinical practice. Roughly how many patients with ALS do you currently manage?

Added By: c_admin
Q2.

What are your initial thoughts on the clinical trial data and scientific literature to date for AMX0035?

Added By: c_admin
Q3.

On a scale from 1-10 (10 being extremely excited), how would you rate your level of excitement for  AMX0035?

Added By: c_admin
Q4.

If AMX0035 gets approved on the existing data available so far, do you expect to begin prescribing AMX0035 to any of your patients?

Added By: c_admin
Q5.

How does AMX0035 compare and fit in with the current standard of care or other treatment options?

Added By: c_admin
Q6.

The Adcom voting question tomorrow: (Do the data from the single randomized, controlled trial and the open-label extension study support a conclusion that sodium phenylbutyrate/taurursodiol is effective in the treatment of patients with amyotrophic lateral sclerosis (ALS)?)

If you were on the panel, how would you vote

Added By: user1ae2bf5f
Q7.

If you are a NO on the Adcom voting question, how would you answer the followup question which is, "what additional information you would consider necessary to support a conclusion that sodium phenylbutyrate/taurursodiol is effective in the treatment of patients with ALS"

Added By: user1ae2bf5f
Q8.

In briefing docs, FDA expressed a few of its major concerns on the primary analysis:
1. mITT, excluding the 2 deaths. (appropriateness of "joint rank" vs. shared baseline mixed effects model used by Amylyx for the analysis)
2. Missing data on week 24 from live patients and how to treat this missing data. (MAR method vs. LOCF by Amylyx)
3. Linearity assumption of ALSFRS-R scale.  

How much weight do you give each of these concerns in terms of how you view the trial results?

When FDA analysis applied, p values go from stat sig 0.038 to 0.06 and 0.08
Does it change your overall view of the product?
Do you believe as a single trial this is still sufficient for an approval? Or does it make you want to see a larger 2nd trial first?

Added By: user1ae2bf5f
Q9.

How do you think the adcom experts will be impacted by these FDA presentations and how do you predict they will they vote?

Thoughts on composition of the expert panel

Added By: user1ae2bf5f
Q10.

On Secondary endpoints
Is this data encouraging?  Not helpful?Numerical trend going against treatment in pNF-H   32.7 pg/mL
Is that large? Small? Meaningful?Numerical difference in rate of SVC decline *in favor of treatment*, of 5% p= .076
Is it meaningful?

Is ATLIS baseline imbalance contributing to slower rate of decline in treatment group?

Overall view on secondary endpoint data

Added By: user1ae2bf5f
Q11.

FDA also raises the issue of the analysis ignoring deaths in open label extension study, when analyzing the ALSFRS slopes, as with primary endpoint.
Is this a real issue?  Or always part of ALSFRS-R analysis?
- Is this different from Radicava which got approval on ALSFRS slope?  
Is this more of an issue because it is a single trial vs. 2 trials?

Added By: user1ae2bf5f
Q12.

FDA raises the issue of Unblinding due to GI and bitter taste--- FDA shows gastrointestinal AEs in first 3 weeks, but it's only around 33% vs. 21%. From your experience is this a difference that is likely to unblind a trial? Is this possibly a less pressing issue being raised by FDA? Or is it important?  Are you concerned about unblinding in the trial when you consider these trial results?

Added By: user1ae2bf5f

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.